Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

24,446 total articles

Smartkem, Inc. and Ferrox Critical Minerals to Combine in All-Stock Merger Valuing Ferrox at $125 Million

Smartkem, Inc. and Ferrox Critical Minerals to Combine in All-Stock Merger Valuing Ferrox at $125 Million

Smartkem, Inc. announced a definitive all-stock merger agreement with Ferrox Critical Minerals, valuing Ferrox at $125 million. The merger positions Smartkem as a vertically integrated public electronics company, now sourcing critical minerals from Ferrox's Tivani project in South Africa, supporting steel, pigment, aerospace, and energy storage sup…

PPHC Acquires Florida Government Relations Firm

PPHC Acquires Florida Government Relations Firm

Public Policy Holding Company, Inc. (PPHC) announced the acquisition of The Advocacy Partners, a leading Florida government relations firm, expanding PPHC's market presence in one of the fastest-growing and economically significant U.S. states. The acquisition is immediately earnings accretive and enhances PPHC's integrated federal-and-state strate…

Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

Ceribell Secures CMS New Technology Add-On Payment (NTAP) for Breakthrough Point-of-Care Delirium Monitor System

Ceribell, Inc. announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has granted a New Technology Add-on Payment (NTAP) for the Ceribell Delirium Monitor System, enabling up to $2,171 additional reimbursement per eligible Medicare patient. This follows FDA clearance of the device and supports faster, objective delirium screening in…

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

Tonix Pharmaceuticals announced positive feedback from a Type C FDA meeting regarding the design of their adaptive Phase 2 field study of TNX-4800, a long-acting human monoclonal antibody aimed at preventing Lyme disease in adults. The study is slated to start in Q1 2027 and will assess both efficacy and safety over a 52-week period, with TNX-4800 …

Aurora Mobile's GPTBots.ai Launches LoopAgent: Production-Grade Execution That Runs Complex Tasks End-to-End

Aurora Mobile's GPTBots.ai Launches LoopAgent: Production-Grade Execution That Runs Complex Tasks End-to-End

Aurora Mobile Limited has announced the launch of LoopAgent, a production-grade execution engine within its GPTBots.ai AI agent platform. LoopAgent enables autonomous handling of complex, multi-step business tasks, offering enterprises enhanced control, security, and auditing capabilities. This development marks a shift towards AI agents that can c…

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

TG Therapeutics reported second quarter 2026 total global revenue of approximately $240 million, driven primarily by BRIUMVI U.S. net product revenue of $228 million, representing a 64% year-over-year increase. The company raised its full-year 2026 global revenue guidance to approximately $950 million, including $890-$905 million for BRIUMVI in the…

Plug Power to Announce 2026 Second Quarter Results on August 10, 2026

Plug Power to Announce 2026 Second Quarter Results on August 10, 2026

Plug Power Inc., a pioneer in hydrogen fuel cell technology and integrated hydrogen solutions, announced it will report its second quarter 2026 financial results on August 10, 2026. The company is a leader in hydrogen production, storage, and fueling infrastructure and supports major global corporations. The results call and webcast details accompa…

Sportradar Reports Second Quarter 2026 Financial Results

Sportradar Reports Second Quarter 2026 Financial Results

Sportradar Group AG posted a 19% increase in revenue for Q2 2026 to €378 million, driven by growth in Betting Technology & Solutions and Sports Content services. Adjusted EBITDA also rose 19% to €76 million with margin expansion. The company expanded its market presence via multi-year partnerships with prediction market platforms Kalshi and Polymar…

BCB Bancorp, Inc. Reports Net Loss of $14.8 Million in the Second Quarter 2026; Board Approves Reincorporation in Delaware, Subject to Shareholder Approval

BCB Bancorp, Inc. Reports Net Loss of $14.8 Million in the Second Quarter 2026; Board Approves Reincorporation in Delaware, Subject to Shareholder Approval

BCB Bancorp, Inc. (NASDAQ: BCBP) reported a net loss of $14.8 million for the second quarter of 2026, a significant deterioration from net income in both the previous quarter and prior year. The loss was driven by a $19 million provision for credit losses, a $5.3 million goodwill impairment, and a $2.6 million loss on loan sales. The company announ…

EVA LIVE INC. ANNOUNCES FORMATION OF EVA DEFENSE ADVISORY BOARD, APPOINTS GENERAL ROBERT BROOKS BROWN (R) AND ROSS MANDEL

EVA LIVE INC. ANNOUNCES FORMATION OF EVA DEFENSE ADVISORY BOARD, APPOINTS GENERAL ROBERT BROOKS BROWN (R) AND ROSS MANDEL

Eva Live Inc. announces the creation of Eva Defense Inc.'s advisory board with the appointments of General Robert Brooks Brown and Ross Mandel. This step initiates Eva Live's expansion into the defense sector, leveraging its AI technology to develop integrated military-grade products such as autonomous drones, command consoles, and resilient commun…

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia

Adlai Nortye Ltd., a clinical-stage biotech company, announced the submission of Clinical Trial Notification to Australia's regulatory body and approval from the Human Research Ethics Committee to begin a global Phase I trial of AN4035, a first-in-class antibody drug conjugate (ADC) targeting CEACAM5 with a pan-RAS(ON) inhibitor payload. The trial …

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics Completes Patient Enrollment in Registrational Phase 3 Trial of OPGx-LCA5 for LCA5-Associated Inherited Retinal Disease

Opus Genetics has completed patient enrollment in its registrational Phase 3 trial of OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease. The trial design aligns with FDA Rare Disease Evidence Principles, aiming for a Biologics License Application submission based on six-month efficacy data expected by the end …

Douglas Dynamics Reports Record Second Quarter 2026 Results

Douglas Dynamics Reports Record Second Quarter 2026 Results

Douglas Dynamics, Inc. (NYSE: PLOW) announced record second quarter 2026 financial results with net sales increasing 10% to $214.6 million and adjusted EBITDA rising 5% to a record $44.6 million. The company reported adjusted diluted EPS growth of 7% to $1.22 and returned $10 million in cash to shareholders. Strong snowfall led to robust preseason …

Brookfield Completes Acquisition of Oaktree

Brookfield Completes Acquisition of Oaktree

Brookfield Asset Management has finalized its acquisition of Oaktree, enhancing its credit investing capabilities and expanding its global reach. The merger strengthens Brookfield's credit business across multiple credit strategies and solidifies the U.S. as its largest market, accounting for over 60% of employees and nearly half of revenue.

Supernus Announces Second Quarter 2026 Financial Results

Supernus Announces Second Quarter 2026 Financial Results

Supernus Pharmaceuticals delivered a 32% increase in total revenues to $219.1 million for Q2 2026, driven by strong sales growth of its CNS-focused products including Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. Collaboration revenue with Biogen on ZURZUVAE further boosted results. The company raised its full-year 2026 revenue guidance and announced an …